These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14717955)

  • 1. Fabry disease: kidney involvement and enzyme replacement therapy.
    Siamopoulos KC
    Kidney Int; 2004 Feb; 65(2):744-53. PubMed ID: 14717955
    [No Abstract]   [Full Text] [Related]  

  • 2. Deceased renal transplantation in patient with Fabry's disease maintained by enzyme replacement therapy.
    Kato T; Nishimura K; Ichikawa Y
    Int J Urol; 2009 Jul; 16(7):650. PubMed ID: 19659805
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnosis and management of kidney involvement in Fabry disease.
    Warnock DG; West ML
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of Fabry disease.
    Kleinert J; Hauser AC; Lorenz M; Födinger M; Sunder-Plassmann G
    Kidney Int; 2004 Sep; 66(3):1288; author reply 1288-9. PubMed ID: 15327431
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease.
    Kosch M; Koch HG; Oliveira JP; Soares C; Bianco F; Breuning F; Rasmussen AK; Schaefer RM
    Kidney Int; 2004 Sep; 66(3):1279-82. PubMed ID: 15327428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
    Pisani A; Riccio E; Sabbatini M
    Genet Med; 2015 Jan; 17(1):21-3. PubMed ID: 25010055
    [No Abstract]   [Full Text] [Related]  

  • 7. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
    Reidt S; Namdar M; Serra A; Krayenbühl PA; Gruner C; Keller DI; Lüscher TF; Schmied C
    Intern Med J; 2014 Feb; 44(2):205-7. PubMed ID: 24528819
    [No Abstract]   [Full Text] [Related]  

  • 8. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [First Polish experience with enzyme replacement therapy in patients with Fabry disease].
    Undas A; Ryś D; Brzeńziiska-Kolarz B; Padjas A; Musiał J
    Pol Arch Med Wewn; 2004 Dec; 112(6):1479-86. PubMed ID: 15962614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
    Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
    Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fatal outcome of a patient with Fabry disease in enzymatic treatment].
    Moyano MJ; del Toro N; Amor J; Milán JA
    Nefrologia; 2005; 25(2):207-8. PubMed ID: 15912661
    [No Abstract]   [Full Text] [Related]  

  • 12. Fabry disease manifesting as chronic uveitis--treated with enzyme replacement therapy.
    Shen YD; Yang CM; Huang JS
    Eye (Lond); 2007 Mar; 21(3):431-2. PubMed ID: 16858434
    [No Abstract]   [Full Text] [Related]  

  • 13. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Fabry disease: Successes, failures, and expectations].
    Lidove O; Barbey F; Joly D
    Nephrol Ther; 2016 Apr; 12 Suppl 1():S105-13. PubMed ID: 26968478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
    Tahir H; Jackson LL; Warnock DG
    J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy.
    Gelderman MP; Schiffmann R; Simak J
    Arterioscler Thromb Vasc Biol; 2007 Jul; 27(7):e138-9. PubMed ID: 17581828
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lisosomal disease with endocrine abnormality].
    Eto Y
    Nihon Rinsho; 2006 Sep; Suppl 3():579-81. PubMed ID: 17022612
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzyme replacement therapy and renal function in 201 patients with Fabry disease.
    Schwarting A; Dehout F; Feriozzi S; Beck M; Mehta A; Sunder-Plassmann G;
    Clin Nephrol; 2006 Aug; 66(2):77-84. PubMed ID: 16939062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.